BioCentury | Nov 30, 2018
Targets & Mechanisms

Revving up metabolism at ASH 2018

Cancer metabolism is a prominent theme at this year’s ASH meeting, with researchers broadening the tent from metabolic targets that drive hematologic malignancies to those that intersect with other hot topics, notably immuno-oncology and epigenetics....
BioCentury | May 23, 2018
Distillery Therapeutics


INDICATION: Graft-versus-host disease (GvHD) Mouse studies suggest inhibiting DOT1L or overexpressing DUSP6 could help treat GvHD associated with T cell therapies. In a mouse model of xenogeneic T cell-associated GvHD, adoptive transfer of human CD8...
BioCentury | May 17, 2018
Preclinical News

Targeting DOT1L, DUSP6 to prevent GvHD

In a Nature Communications study , scientists at University Health Network and University of Toronto showed that inhibiting histone methyltransferase DOT1L or promoting dual specificity phosphatase 6 (DUSP6; MKP3) could help prevent graft-versus-host disease induced by...
BioCentury | Mar 1, 2018
Translation in Brief

New Therapeutic Targets and Biomarkers: February 2018

New Therapeutic Targets and Biomarkers: February 2018 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database during February 2018. Therapeutic targets are defined as any protein, gene or other...
BioCentury | Feb 8, 2018
Translation in Brief

Diverging pathways

Results from a National Cancer Institute study could explain disparities in treatment outcomes for African-Americans, who have the highest lung cancer incidence and mortality rates of any racial group. The study, published in Clinical Cancer...
BioCentury | Oct 10, 2017
Distillery Therapeutics


INDICATION: Depression Patient sample and mouse studies suggest promoting DUSP3 expression could help treat major depressive disorder (MDD) in female patients. In postmortem tissue samples from the ventromedial prefrontal cortex of 26 MDD patients and...
BioCentury | May 11, 2017
Tools & Techniques

Stemming the tide

...cell activity - in vitro , compared with either agent alone March 2014 Dual specificity phosphatase 4 (DUSP4; MKP2...
...c-jun N-terminal kinase (JNK); MEK Breast cancer Inhibition of MEK and JNK or overexpression of DUSP4...
BioCentury | Apr 25, 2017
Distillery Therapeutics


...In patients, low levels of the DUSP4 negative regulator IL-4 , and high levels of DUSP4...
...or overexpression of DUSP4 decreased proliferation, invasiveness and colony formation compared with vehicle or normal DUSP4...
...a CD124-binding mAb, in preclinical testing to treat atopic dermatitis and asthma. TARGET/MARKER/PATHWAY: Dual specificity phosphatase 4 (DUSP4; MKP2...
BioCentury | Mar 28, 2017
Distillery Therapeutics


INDICATION: Chronic myelogenous leukemia (CML) In vitro and mouse studies suggest combining Gleevec imatinib with inhibition of c-fos and DUSP1 could help treat CML. In patient peripheral blood monocytes (PBMCs), levels of c-fos and DUSP1...
BioCentury | Jan 25, 2017
Distillery Therapeutics

Endocrine / Metabolic

INDICATION: Obesity Mouse studies suggest fecal microbiotal transplants from DUSP6 -deficient donors could help treat obesity. In mice fed a high-fat diet, DUSP6 knockout decreased the permeability of gut epithelial cells and weight gain compared...
Items per page:
1 - 10 of 23